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Abbreviation 
GVHD: graft-versus-host disease 
HCT: hematopoietic cell transplantation 
HR: hazard ratio 
 
IL10: interleukin 10 
IL10RB: interleukin 10 receptor β  
NRM: non-relapse mortality 
SNP: single nucleotide polymorphism 
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Abstract   
Background. Results of a previous study with HLA-identical siblings showed individual and synergistic 
associations of single nucleotide polymorphisms in the promoter region of the recipient’s IL10 gene and 
the donor’s IL10 receptor β (IL-10RB) gene with development of grades III-IV acute graft-versus-host 
disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT).  
Methods. In the current study of 936 patients who had unrelated donors, genotypes of single nucleotide 
polymorphisms in the IL10 gene and the IL-10RB gene were evaluated as correlates with outcomes after 
transplantation.  
Results. We found no statistically significant associations of polymorphisms at positions –3575, -2763, –
1082, and –592 of the IL10 gene or codon 238 of the IL10RB gene with severe acute GVHD, extensive 
chronic GVHD or non-relapse mortality after HCT. Among HLA-matched unrelated pairs, the patient’s 
IL10/-592 genotype and donor’s IL10RB/c238 genotype showed trends suggesting individual and 
combined associations with grades III-IV acute GVHD similar to those observed among patients with 
HLA-identical sibling donors.  
Conclusions. Although genetic variation in IL10 pathway affects risk of acute GVHD and non-relapse 
mortality in HLA-identical sibling transplants, the current results indicate that genetic variation in the 
IL10 pathway does not significant affect these outcomes in unrelated donor transplants suggesting that the 
strength of the alloimmune response in the latter exceeds the anti-inflammatory activity of IL10. 
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Introduction 
Graft-versus-host disease (GVHD) remains a major complication associated with morbidity and mortality 
of hematopoietic stem cell transplantation (HCT) (1).  Matching for donor and recipient HLA alleles 
reduces risk of acute GVHD and improves outcomes after HCT (2-5). Polymorphisms in numerous non-
MHC genes encoding cellular proteins that function as minor histocompatibility antigens also cause 
GVHD (6).  Variation in other immune response genes contribute to GVHD by modulating the intensity 
of alloreactive T cells, inflammation and other components of the innate immune systems (7-9). 
 
Genetic polymorphism in the promoter region of the IL10 gene has a significant impact on outcomes after 
HCT with HLA-identical sibling donors (10-12). In our previous study of single nucleotide 
polymorphism (SNP) among 993 HLA-identical sibling transplants, the presence of the IL10/-592*A 
allele in the patient was significantly associated with lower risks of grades III-IV acute GVHD and non-
relapse mortality (NRM) (12). Results of an analysis of extended IL10 promoter region haplotypes 
defined by five SNPs at positions –3575, -2763, –1082, -819 and –592 showed that the -592*A allele 
served to identify the promoter haplotype (T-C-A-T-A). A subsequent study of the same population 
revealed the donor c238*G allele of the IL10 receptor β gene (IL10RB/c238) was associated with a 
reduced risk of grades III-IV acute GVHD among patients with the lower-risk IL10/-592 A/C or A/A 
genotypes but not among those with the high risk IL10/-592 C/C genotype. These results suggested that 
interactions of the patient IL10/-592 and donor IL10RB/c238 genotypes influence the risk of GVHD, 
supporting the hypothesis that the IL10 pathway can play an important role in controlling the severity of 
acute GVHD (13). In the current study, IL10 promoter and IL10RB/c238 genotypes were determined 
among a large cohort of patients who had HCT from unrelated donors to determine whether genetic 
variations in the IL10 pathway convey effects similar to those observed among patients with HLA-
identical sibling donors.   
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Materials and Methods 
Study populations. The study population consisted of patients who had HCT from unrelated donors at 
the Fred Hutchinson Cancer Research Center between 1985 and 2002 (Table 1). Among approximately 
1600 unrelated HCT cases, 936 had DNA samples retrieved from patients, donors or both patients and 
donors for genotyping. All patients were prepared with myeloablative conditioning regimens, and more 
than 90% received methotrexate and cyclosporine after HCT.  Indications for HCT included acute 
lymphoblastic leukemia (n=130), acute myelogenous leukemia (n=174), chronic myelogenous leukemia 
(n=538), other hematopoietic malignancies (n=12), and non-malignant disorders including 
myelodysplastic syndrome (n=82).  
 
Histocompatibility testing and donor selection criteria have been described previously (14). High 
resolution sequencing method was used to type the alleles of exons 2 and 3 of the class I HLA-A, -B and 
–C genes. A combination of genotyping with high resolution sequence specific oligonucleotide probes 
(SSOP) followed, when necessary, by sequencing of exon 2 was used to assess matching of the class II 
DRB1 and DQB1 genes. Patient and unrelated donor were classified as HLA-matched if they had the 
same HLA-A, B, C and DRB1 alleles. Mismatching was defined as the presence of a donor antigen or 
allele not shared by the recipient or the presence of a recipient antigen or allele not shared by the donor. 
Among the 818 cases with DQ typing data available, 423 were either fully matched (n=387) or 
mismatched for only a single HLA-DQ antigen or allele (n=36). For purposes of the current analysis, 
these 423 cases were defined as the HLA-matched group. All patients and donors gave written informed 
consent according to protocols approved by the Fred Hutchinson Cancer Research Center Institutional 
Review Board. 
    
Genotyping of SNPs. Genotypes of SNPs at -3575 (rs1800890), -2763 (rs6693899), -1082 (rs1800896) 
and -592 (rs1800872) of the IL10 gene and c238 (rs2834167) of the IL10RB gene were determined by 
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polymerase chain reaction/restriction fragment length polymorphism as described previously (12-13). 
Complete genotyping for the four IL10 SNPs was performed for 692 patients and 697 donors. An 
additional 204 donors were genotyped for IL10/-592 and IL10/-1082 with the use of the Illumina 
BeadarrayTM platform (15-16). All 901 donor samples were tested for IL10RB/c238 genotype, and results 
were informative in all but 2 samples.  
 
Analysis of Clinical Outcomes.  The data were analyzed in February 2008 with a median follow-up of 
the surviving patients at 121 months (5-251 months). Genotypes were correlated with the incidence rates 
of severe (grades III-IV) acute GVHD, extensive chronic GVHD and non-relapse mortality (NRM) by 
using proportional hazards regression models and multivariate analysis with adjustment for patient age at 
transplant (continuous), donor-recipient sex mismatch, use of total body irradiation in the conditioning 
regimen, disease risk group, and source of stem cells (bone marrow vs. peripheral blood) as described 
previously (12-13). Transplant year (continuous) was included in the multivariable analysis because of 
increased sensitivity for diagnosing gut GVHD after 1991 and use of prophylactic fluconazole and 
ganciclovir as a standard of post-transplant care since 1992. HLA match status was not included in the 
multivariable analysis, but instead a separate subset analysis was performed to evaluate the potential 
effect of HLA-mismatch. An analysis of HLA-DP, a recently discovered risk factor for acute GVHD (17), 
was not included since there was no significant difference in the distribution of HLA-DP mismatches 
among the 3 IL10 and IL10RB genotypes.  Acute and chronic GHVD were diagnosed and graded 
according to standard criteria (18-19). NRM was defined as death before recurrent malignancy. The 
cumulative incidence of acute GVHD, chronic GVHD and NRM were estimated according to the 
methods of Andersen et al. (20). Death was considered as a competing risk for analysis of acute and 
chronic GVHD, and recurrent malignancy was considered as a competing risk for analysis of chronic 
GVHD and NRM. Follow-up was censored at the time of a competing event.   
 
All P values are two-sided and derived from likelihood ratio statistics from the proportional hazards 
regression models. Tests for trend were carried out by assigning the ordinal values 1, 2, and 3 to the 
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genotypes M/M, M/m, and m/m, respectively and testing the association of the resulting variable with 
outcome. “M” represents the more frequent (major) allele, and “m” represents the less frequent (minor) 
allele in the studied population. 
 
Results 
Genotype and transplant outcomes among overall study population. The cumulative incidence of 
grades III-IV acute GVHD at day 100 after unrelated HCT was 37%, compared to 19% after HCT from 
HLA-identical siblings (Table 1). The cumulative incidence of NRM at 5 years after unrelated HCT was 
39%, compared to 25% after HCT from HLA-identical siblings. No statistically significant associations 
were observed between the IL10 patient or donor genotypes or the IL10RB donor genotype and the risks 
of grades II-IV acute GVHD (data not shown), grades III-IV acute GVHD, extensive chronic GVHD or 
NRM after unrelated HCT (Table 2). The cumulative incidence rates of grades III-IV acute GVHD at day 
100 were 36%, 39% and 33% with patient IL10/-592 C/C, A/C and A/A genotypes, respectively (trend 
hazard ratio: 1.0; trend P = 0.77), and 38%, 35% and 39% with donor IL10RB/c238 A/A, A/G and G/G 
genotypes, respectively (trend hazard ratio: 0.9; trend P = 0.51).   
 
IL10/IL10RB genotype and acute GVHD in HLA-matched unrelated transplants. To determine 
whether HLA mismatching in this cohort of unrelated HCT recipients might confound detection of an 
association between IL10 and IL10RB genotypes and severe acute GVHD, we examined the effect of 
IL10 and IL10RB variation in the HLA-matched subset (n = 423). In this analysis, we found trends 
similar to those observed among patients with HLA-identical sibling donors (Table 3). The trend hazard 
ratio was 0.8 (trend P = 0.23) for association of the IL10/-592*A allele in the patient with a lower 
incidence of grades III-IV acute GVHD. Likewise, the trend hazard ratio was 0.8 (trend P = 0.15) for 
association of the IL10RB/c238*G allele in the donor with a lower incidence of grades III-IV GVHD. A 
significant association with grades III-IV acute GVHD was observed for the IL10/-1082 genotype of the 
donor (trend hazard ratio: 1.3; trend P=0.02). The cumulative incidences of grades III-IV acute GVHD at 
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day 100 were 25%, 39%, and 40% for patients with donor IL10/-1082*A/A, A/G, and G/G genotypes, 
respectively (Table 3).  
 
Combined analysis of patient IL10/-592 genotypes and donor IL10RB/c238 genotypes. In the 
previous report among 953 HLA-identical sibling transplants (13), the patients were stratified into 9 
groups according to the IL10/-592 genotype of the patient and the IL10RB/c238 genotype of the donor to 
examine the combined effect of IL10 and IL10RB SNPs on severe acute GVHD. As reported previously 
(13), a beneficial effect of the IL10RB*G allele in the donor was observed only among patients with the 
IL10/-592* A/A and A/C genotypes, but not among patients with IL10/-592 C/C genotype. The trend 
hazard ratios for the IL10RB/c238* G allele were 0.6 and 0.7 among HLA-matched unrelated transplant 
patients with IL10/-529 A/C and A/A genotype, respectively and 0.5 and 0.4 among HLA-identical 
sibling transplant patients with IL10/-529 A/C and A/A genotype, respectively (Table 4).  
 
Discussion   
Polymorphisms in the promoter region of the IL10 gene have been associated with GVHD and NRM after 
HCT from an HLA-identical sibling donor (10-12). In previous reports, we have shown the IL10/-592*A 
allele and the IL10RB/c238*G alelle were significantly associated with lower risk of severe acute GVHD 
(trend hazard ratio: 0,7 and 0.7, respectively). In unrelated HCT, the presence of IL10R2-G-C-C or the 
absence of IL10R3-G-C-C haplotype, defined by a microsatellite (IL10R) and 3 SNPs (-1082, -819 and -
592), was associated with a higher risk of NRM in a cohort of 132 patients (21), and the presence of 
alleles 12, 14 or 15 of IL-10G (or IL10/-1064) microsatellite polymorphism was  associated with a higher 
risk for NRM among a cohort of 131 patients (22). However, significant association of IL10 gene 
polymorphism with GVHD after unrelated HCT has not been reported. In the current study of unrelated 
HCT, statistically significant associations of the patient IL10/-592 or donor IL10RB/c238 genotypes with 
severe acute GVHD were not detected, unlike results previously reported in our study of HCT with HLA-
identical sibling donors (12-13). Among HLA-matched unrelated pairs, however, the patient’s IL10/-592 
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genotype and donor’s IL10RB/c238 genotype showed trends suggesting individual and combined 
associations with grades III-IV acute GVHD similar to those observed among patients with HLA-
identical sibling donors.  
 
IL10 downregulates immune response and may facilitate the induction of tolerance after allogeneic 
transplantation (23-26).  Holler et al. and Baker et al., have shown that higher IL10 production after ex-
vivo stimulation of recipient’s cells before transplantation is associated with reduced risks of acute 
GVHD and non-relapse mortality (27-28). However, elevated serum IL10 concentration after 
transplantation has been associated with increased risks of acute GVHD and non-relapse mortality (29-
30). The administration of exogenous IL10 in murine allogeneic transplantation models also has 
inconsistent effect (31-33).  Conflicting results have been reported regarding the genetic controls of IL10 
production (34-37). Previous studies have reported that IL10 G-C-C haplotype (defined by -1082, -819 
and -592) is associated with higher IL10 production in vitro. The association of IL10/-1082*G allele, 
IL10/-592*C allele, or G-C-C haplotype in patients with a higher risk of acute GVHD and autologous 
GVHD (11-13, 38) have lead to the assumption that IL10 may promote alloimmune response (38). 
Results from other studies, however, have shown an association of the G-C-C haplotype with lower IL10 
production in vitro (36-37).  
 
The IL10 receptor complex is composed of 2 subunits, IL10 receptor α (IL10RA) and IL10RB. IL10RB 
functions as an accessory subunit for signaling when IL10 binds to IL10RA (39). The substitution of 
nucleotide A by nucleotide G at position cDNA 238 results in an amino acid change at codon 47 of Lys 
by Glu (K47E) and is located at the first extracellular FnIII domain repeat of IL10RB (13, 40). Frodsham 
et al. have shown that the IL-10RB/c238*G allele is associated with higher mRNA production, higher 
surface expression of IL10RB, and greater IL10-mediated inhibition of LPS-induced TNFα production 
(41), suggesting that the IL10/c238*G allele in the donor may allow for a higher level of IL10 signal 
transduction and thereby increase the immune suppressive activity of the IL10 pathway. The synergistic 
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effect of IL10/-592*A allele in patients and IL10RB/c238*G allele in donors on the reduction of GVHD 
incidence indicates the IL10 pathway is regulated by functional polymorphisms that result in variable 
IL10 production by recipients and variable signal transduction through the IL10 receptor on the donors 
cells. 
 
The incidence and severity of acute GVHD is greater in unrelated donor compared to HLA-identical 
HCT.  However, the relative risks of grades III-IV acute GVHD were only 1.2 to 1.4 and 1.4 to 1.9 for the 
mismatch of HLA-A, B, C and DRB1 among two large cohorts of unrelated transplant performed under 
the auspices of the National Marrow Donor Program (NMDP) in the United States (n= 1874) and Japan 
(n=1298), respectively (3,5), and was 2.0 for mismatch of both class I and class II antigens among 
patients who had HCT at our center (42). The recent retrospective study of high resolution HLA-typing 
from NMDP also demonstrated that the relative risk for any single HLA-A,B, C or DRB1 mismatch was 
1.5 (43). The more intense allo-immune reaction elicited by mismatching for HLA and minor 
histocompatibility antigens in unrelated HCT may diminish the relative effects of other individual risk 
factors for severe GVHD. Although a weak association of a higher risk of severe acute GVHD with 
IL10/-1082*G allele of donors was observed among both HLA-identical sibling transplants (HR=1.2) and 
HLA-matched unrelated transplants (HR= 1.3), the decreased risk of grades III-IV acute GVHD 
associated with the IL10/-592*A allele among patients with HLA-identical sibling donors (HR=0.8) was 
not observed among those with HLA-matched unrelated donors (HR=1.0) (Table 3). Further studies with 
larger HLA-matched unrelated transplant populations will be necessary in order to elucidate the potential 
weak effects of donor’s IL10 promoter genotype on the development of severe acute GVHD. 
 
Our current results do not exclude the possibility that the IL10/-592*A allele of the patient and IL-
10RB/c238*G allele of the donor have individual and combined effects that reduce the risk of severe 
acute GVHD after unrelated HCT.  The magnitude of these individual effects relative to the higher overall 
incidence of acute GVHD after unrelated HCT appears to be smaller than observed after HCT with HLA-
matched sibling donors. Our results suggest that efforts to detect associations between genetic risk factors 
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and acute GVHD are likely to be more productive in studies of HCT with HLA-identical sibling donors 
than in studies with unrelated donors.   
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Table 1.  Characteristics of patients with unrelated donors and HLA-identical sibling donors (12) 
 
Characteristic 
 
Unrelated transplant 
Number (%) 
 
Sibling transplant 
Number (%) 
   
HLA compatibility, n (%) 
    Matched a 
    mismatched 
    unknown 
 
423 (45) 
395 (42) 
118 (13) 
 
993 (100) 
0 
0 
   
Age, median years (range) 35 (<1 – 59) 38 (<1-67) 
   
Transplant year, n (%) 
    1985-1991 
    1992-2002 
 
159 (17) 
777 (83) 
 
391 (39) 
602 (61) 
   
 Gender match (patient/donor), n (%) 
    Male/Male 
    Male/Female 
    Female/Male 
    Female/Female 
 
 329 (35) 
202 (22) 
234 (25) 
171 (18) 
 
332 (33) 
250 (25) 
189 (19) 
           222 (22) 
   
Total body irradiation, n (%)  
    yes 
    no 
 
858 (92) 
78 (8) 
 
537 (54) 
456 (46) 
   
Disease group, n (%) b 
    non-malignant disease 
    low risk malignancy 
    high risk malignancy 
 
82 (9) 
546 (58) 
308 (33) 
 
170 (17) 
497 (50) 
326 (33) 
   
Source of stem cells, n (%) 
    bone marrow 
    peripheral blood 
 
905 (97) 
31 (3) 
 
848 (85) 
145 (15) 
   
Outcomes, cumulative incidence 
    Grades II-IV acute GVHD (day 100) 
    Grades III-IV acute GVHD (day 100) 
    Clinical extensive chronic GVHD (5 years) 
    Non-relapse mortality (5 years) 
 
86% 
37% 
52% 
39% 
 
56% 
19% 
43% 
25% 
a patient and donor matched for HLA-A, B, C and DRB1 
b non-malignant disease: aplastic anemia, immune deficiency disorder, lymphoproliferative disease, 
myelodysplastic syndrome and paroxysmal nocturnal hematuria;  low risk malignancy: acute 
lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) or non-Hodgkin lymphoma (NHL) in 
remission and chronic myelogenous leukemia (CML) in chronic phase;  high risk malignancy: ALL, AML, 
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chronic lymphocytic leukemia, NHL in relapse, CML beyond chronic phase, multiple myeloma and 
Hodgkin’s disease.     
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Table 2. Outcomes after unrelated hematopoietic cell transplantation, according to IL10 promoter region and 
IL10RB/c238 genotypes  
         
Grades III-IV acute GVHD a 
 
 
Extensive chronic GVHD 
 
 
Non-relapse mortality 
 
 
 
Gene/SNP 
 
 
 
Genotype (n)b 
 
 
 
Incidencec 
 
Trend 
hazard ratiod 
 
 
Trend 
P value 
 
 
Incidencec 
 
Tr rend  haza
d ratiod  
 
 
Trend 
P value 
 
 
Incidencec 
 
Trend  
hazard ratiod  
 
 
Trend 
P value 
Patients 
(n=692)  
  
IL10/-592 
  
 
 
IL10/-1082  
  
 
 
IL10/-2763 
  
 
 
IL10/-3575  
  
 
 
 
C/C (402) 
A/C (235) 
A/A  (55) 
 
A/A (200) 
A/G (338) 
G/G (154) 
 
C/C (313) 
A/C (299) 
A/A  (80) 
 
T/T (291) 
A/T (301) 
    A/A (100) 
 
 
36% 
39% 
33% 
 
36% 
37% 
38% 
 
40% 
33% 
40% 
 
39% 
35% 
     36% 
 
 
 
1.0 
(0.9-1.3) 
 
 
1.0 
(0.9-1.2) 
 
 
0.9 
(0.8-1.1) 
 
 
0.9 
(0.8-1.1) 
 
 
 
0.72 
 
 
 
0.60 
 
 
 
0.49 
 
 
 
0.37 
 
 
 
52% 
54% 
47% 
 
51% 
51% 
55% 
 
51% 
51% 
59% 
 
49% 
55% 
49% 
 
 
 
1.0 
(0.9-1.2) 
 
 
1.1 
(0.9-1.2) 
 
 
1.0 
(0.9-1.2) 
 
 
1.0 
(0.9-1.2) 
 
 
 
0.92 
 
 
 
0.53 
 
 
 
0.61 
 
 
 
0.96 
 
 
 
37% 
40% 
44% 
 
39% 
39% 
39% 
 
41% 
37% 
34% 
 
42% 
35% 
     39% 
 
 
 
1.2 
(1.0-1.4) 
 
 
1.0 
(0.8-1.1) 
 
 
0.9 
(0.7-1.0) 
 
 
0.9 
(0.7-1.1) 
 
 
 
0.09 
 
 
 
0.70 
 
 
 
0.08 
 
 
 
0.19 
 
Donors 
(n=901)  
 
IL10/-592   
 
 
  
IL10/-1082  
 
 
 
IL10/-2763  
 
 
 
IL10/-3575  
 
 
 
IL10RB/c238  
 
 
 
C/C (505) 
A/C (350) 
A/A  (46) 
 
A/A (256) 
A/G (433) 
G/G (212) 
 
C/C (285) 
A/C (305) 
A/A (107) 
 
T/T (267) 
A/T (328) 
A/A (102) 
 
A/A (455) 
A/G (364) 
G/G   (80) 
 
 
35% 
39% 
46% 
 
36% 
40% 
34% 
 
35% 
39% 
35% 
 
36% 
38% 
33% 
 
38% 
35% 
39% 
 
 
 
 
1.1 
(0.9-1.3) 
 
 
1.0 
(0.9-1.2) 
 
 
1.1 
(0.9-1.3) 
 
 
1.0 
0.8-1.2) 
 
 
0.9 
(0.8-1.1) 
 
 
 
0.24 
 
 
 
0.97 
 
 
 
0.55 
 
 
 
0.94 
 
 
 
0.51 
 
 
52% 
53% 
46% 
 
53% 
52% 
51% 
 
49% 
54% 
55% 
 
48% 
55% 
52% 
 
55% 
48% 
49% 
 
 
 
1.1 
(0.9-1.3) 
 
 
1.0 
(0.8-1.1) 
 
 
1.0 
(0.9-1.2) 
 
 
1.1 
(0.9-1.2) 
 
 
0.9 
(0.8-1.1) 
 
 
 
0.33 
 
 
 
0.44 
 
 
 
0.69 
 
 
 
0.53 
 
 
 
0.27 
 
 
37% 
42% 
39% 
 
41% 
38% 
37% 
 
39% 
36% 
37% 
 
39% 
36% 
40% 
 
37% 
43% 
34% 
 
 
 
1.1 
(1,0-1.4) 
 
 
0.9 
(0.8-1.1) 
 
 
1.0 
(0.8-1.1) 
 
 
1.0 
(0.8-1.2) 
 
 
1.1 
(0.9-1.2) 
 
 
 
0.11 
 
 
 
0.34 
 
 
 
0.66 
 
 
 
0.99 
 
 
 
0.53 
a  Grading of acute GVHD was not available for 16 patients. 
b Genotyping of IL10/-2763 and IL10/-3575 was performed in 697 donors, and genotyping of 
IL10RB/c238 was not informative in 2 donor samples. 
c Cumulative incidence of grade III-IV acute GVHD, extensive chronic GVHD and non-relapse mortality 
at day 100, 5 years and 5 years, respectively. 
d 95% confidence intervals were indicated in the parentheses. 
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Table 3. Grades III – IV acute GVHD, according to IL10 and IL10RB/c238 genotypes among HLA-
matched unrelated transplants 
         
HLA-matched unrelated transplant (n = 423) a 
 
  
 
 
 
 
Gene/SNP 
 
 
 
Genotype, (N) b 
 
 
 
Incidence c 
 
Trend 
hazard ratio d 
 
 
Trend 
P value 
 
 
  
 
  
 
 
  
Patients   
  
IL10/-592 
  
 
 
IL10/-1082  
  
 
 
IL10RB/c238  
 
 
C/C (196) 
A/C (111) 
A/A (25) 
 
A/A (90) 
A/G (163) 
G/G (79) 
 
A/A (0) 
A/G (0) 
G/G (0) 
 
 
36% 
35% 
24% 
 
33% 
35% 
37% 
 
 
ND 
 
 
 
0.8 
(0.6-1.1) 
 
 
1.1 
(0.8-1.4) 
 
 
ND  
 
 
 
0.23 
 
 
 
0.48 
 
 
 
ND  
 
 
  
 
  
 
   
 
 
 
  
 
 
 
  
 
 
 
    
 
 
 
  
 
 
 
  
 
 
 
   
 
  
        
Donors  
 
IL10/-592   
 
 
  
IL10/-1082  
 
 
 
IL10RB/c238  
 
 
 
 C/C (223) 
A/C (157) 
A/A (17)  
 
 A/A (110) 
A/G (205) 
G/G (82) 
 
A/A (203) 
A/G (152) 
G/G (38) 
  
 
35% 
35% 
41% 
 
25% 
39% 
40% 
 
38% 
32% 
34% 
 
 
 
1.0  
(0.7-1.3) 
 
 
1.3 
(1.0-1.7) 
 
 
0.8 
(0.6-1.1) 
 
 
 
0.83  
 
 
 
0.02 
 
 
 
0.15 
 
 
  
 
  
 
   
 
 
 
  
 
 
 
    
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
  
 
a matched for HLA-A, B, C and DRB1 alleles. Genotypes were determined among 332 patients and 397 
donors respectively. ND: not done.    
b The numbers in the parenthesis indicates number of unrelated transplants. 
c cumulative incidence of grades III-IV acute GVHD at day 100. 
d 95% confidence intervals were indicated in the parentheses. 
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Table 4. Grades III – IV acute GVHD, according to combined patient IL10/-592 and donor IL10RB/c238 
genotypes, comparing results with unrelated versus related recipients 
Genotype Overall unrelated transplant (n=639)a HLA-matched unrelated transplant (n=311)a  HLA-identical sibling transplant (n=953)b 
Patient 
IL10/-592 
Donor 
IL10RB 
Incidence     
of GVHD c 
Trend  
 
hazard ratiod 
Trend 
P valued 
Incidence     
of GVHD c 
Trend  
 
hazard ratiod 
Trend 
P valued 
Incidence     
of GVHD c 
Trend  
 
hazard ratiod 
Trend 
P valued 
 
C/C 
 
 
 
A/C 
 
 
 
A/A 
 
 
 
A/A  
A/G  
G/G 
 
A/A 
A/G  
G/G  
 
A/A 
A/G  
G/G 
 
37% (189) 
34% (154) 
47% (30) 
 
40% (105) 
37% (97) 
31% (16) 
 
35% (23) 
12% (17) 
63% (8) 
 
 
1.0 
(0.8-1.3) 
 
 
0.9 
(0.6-1.3) 
 
 
1.1 
(0.5-2.6) 
 
 
0.82 
 
 
 
0.46 
 
 
 
0.83 
 
37% (97) 
36% (72) 
38% (16) 
 
40% (48) 
28% (46) 
30% (10) 
 
33% (9) 
0% (8) 
40% (5) 
 
 
1.0 
(0.7-1.4) 
 
 
0.6 
(0.3-1.1) 
 
 
0.7 
(0.1-4.2) 
 
 
0.87 
 
 
 
0.09 
 
 
 
0.74 
 
22% (292) 
22% (183) 
24% (29) 
 
22% (190) 
11% (141) 
8%  (37) 
 
15% (33) 
9% (32) 
0% (16) 
 
 
1.0 
(0.8-1.4) 
 
 
0.5 
(0.3-0.8) 
 
 
0.4 
(0.1-1.2) 
 
 
0.81 
 
 
 
0.004 
 
 
 
0.07 
a Among the 655 patients with paired patient/donor samples available, 320 pairs were matched for HLA-A, B, 
C and DRB1 alleles. Grading of acute GVHD was not available for 16 patients. 
b results from a cohort of 953 recipients with HLA-identical sibling donors (12-13). 
c cumulative incidence of grades III-IV acute GVHD at day 100. Numbers of cases are indicated in 
parentheses. 
d The trend hazard ratios and trend P values were analyzed within each stratum of patients IL10/-592 
genotype. 95% confidence intervals were indicated in the parentheses. 
 
 
 
 
